ClinicalTrials.gg
Sign In
DrugRead study by study

Semaglutide clinical trials

Also written Ozempic, Wegovy, NN9535 and NN9924.

studies test it
450
open now
190
in phase 3
130
first study started
2007
ClinicalTrials.gov finds 806 studies for Semaglutide. How that becomes 450 here

Every study that search finds has been read, apart from the 14 newest, to see whether and how it gives Semaglutide. ClinicalTrials.gov counts as of Nov 14, 2026. How drug pages count

  1. 806Found by its intervention search · See all 806 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 651 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −13
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. −6New since the last reading, not read yet
  4. 787Give Semaglutide to participants
  5. −146Observe patients on it, or give it outside a trial
  6. −69Compare another treatment with it
  7. −122Give it beside what is tested
  8. 450Test it: the count on this site

Get an email when these change. Save the Semaglutide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
5 Dec 2017 · OZEMPIC · NDA 209637 (FDA, Drugs@FDA)
European Union
8 Feb 2018 · Ozempic · EMEA/H/C/004174 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Semaglutide
221
Oral semaglutide
17
Semaglutide Pen Injector
14
Semaglutide Injectable Product
10
Semaglutide 1.0 mg
9

Brand

Ozempic
44
Wegovy
31
Rybelsus
8
Rybelsus 7 mg
2
Rybelsus 3 mg
1
Rybelsus 14 mg
1

Development codes

NN9535
4
NN9924
2
GP40221
1
NNC 0113-0217
1
QLG2065
1

In one entry with another drug

Given together, or one or the other

Cagrilintide and Semaglutide
2

Studies by the year they started

440 studies that test it; most in 2026 (80); 10 more planned to start later

Studies that test Semaglutide, by start year
YearStudies
20071
20081
20093
20112
20124
20138
201419
20153
201612
201711
201813
201931
202011
202132
202249
202347
202457
202556
202680

By phase

A phase 1/2 study counts in both.

Early Phase 1
6
Phase 1
93
Phase 2
99
Phase 3
130
Phase 4
104
No phase
41

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Diabetes Mellitus, Type 2
135
Obesity
91
Diabetes Mellitus, Type 1
13
Diabetes Mellitus
7
Obesity, Morbid
7
Alzheimer Disease
6
Atrial Fibrillation
5
Pediatric Obesity
5
Polycystic Ovary Syndrome
5
Ischemic Stroke
5
Non-alcoholic Fatty Liver Disease
5
Prostatic Neoplasms
3

Who runs them

Industry 176 · Other 274

Novo Nordisk A/S (153) · University of Colorado, Denver (8) · Yale University (6) · Mayo Clinic (5) · University Medical Centre Ljubljana (5) · General Committee of Teaching Hospitals and Institutes, Egypt (5) · University Health Network, Toronto (4) · Vanderbilt University Medical Center (4)

Often tested with

Tested in the same studies.

Tirzepatide (23) · Empagliflozin (9) · Dapagliflozin (8) · GLP-1 Mimetic (5) · GLP-1 receptor agonists (5) · Finerenone (5) · Metformin (4) · Liraglutide (4)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 21 phase 3 studies under way

Semaglutide is the comparator. A study of two new drugs counts under both.

  • 4Zenagamtide · Novo Nordisk A/S · next primary completion Jul 2028
  • 3Bofanglutide · Carnot Laboratories, Gan & Lee Pharmaceuticals. · next primary completion Jun 2027
  • 2BGM0504 · BrightGene Bio-Medical Technology Co., Ltd. · next primary completion Apr 2027
  • 2Ribupatide · Kailera, Fujian Shengdi Pharmaceutical Co., Ltd. · next primary completion Mar 2027
  • 1Retatrutide · Eli Lilly and Company
  • 1Mazdutide · Innovent Biologics (Suzhou) Co. Ltd. · next primary completion Dec 2026
  • 1Cagrilintide · Novo Nordisk A/S · next primary completion Jun 2028
  • 1Bilpatide · Guangdong Raynovent Biotech Co., Ltd · next primary completion Dec 2026
New treatments tested with it · 8 most studied

New when their studies opened, with Semaglutide beside them; studies of each.

Reaching primary completion within a year · 64, 7 in phase 3

Studies that test Semaglutide, phase 3 first.

Studies

Open first, then newest update. How each study uses Semaglutide has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 450

See all 450 studies that test Semaglutide →

Behind its US label · 9 — the studies the FDA label of OZEMPIC, WEGOVY describes

From the Clinical Studies section of OZEMPIC (2026-07), WEGOVY (2026-06), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 288 — no other medicine in its arm

Showing 20 of 288. See all 288 →

Tested with established drugs · 46 — they are given beside it

Showing 20 of 46. See all 46 →

Tested in a combination · 116 — another drug in the study is under test too

Showing 20 of 116. See all 116 →

Beside an established treatment under test · 6 — an approved drug, surgery or radiation is what the study tests

Tested with Semaglutide: Tirzepatide 1 · Probenecid 1 · Cyclosporine 1 · finerenone 1 · Metformin 1 · Sirolimus 1 · Naltrexone 1 · pramlintide 1

Beside a new treatment under test · 75 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with Semaglutide: cagrilintide 30 · NNC0480-0389 3 · ostarine 2 · zalfermin 2 · linafexor 2 · insulin icodec 2 · AT673 1 · CS060380 1

Showing 20 of 75. See all 75 →

Beside supportive care · 32 — a supportive treatment or test is studied

Showing 20 of 32. See all 32 →

One option of several · 8 — a test or a strategy chooses among drugs
Given beside what is tested · 2 — usual care or a partner of the new treatment
As the comparator · 69 — what is tested is compared with Semaglutide

Showing 20 of 69. See all 69 →

Observed · 146 — patients on it are followed, or it is given outside a trial

Showing 20 of 146. See all 146 →

What changed recently

From the registry's own updates since Oct 15, 2026.

Started recruiting6

Show 1 more

Results posted3

Newly registered9

Show 4 more

Codes

What other systems call Semaglutide · ClinicalTrials.gg INT006888

  • MeSH (NLM) D000099194SemaglutideConfirmed NLM, Wikidata
  • UNII (FDA) 53AXN4NNHXSEMAGLUTIDEConfirmed FDA, NLM, Wikidata
  • RxNorm 1991302Confirmed FDA, Wikidata
  • Wikidata Q27261089semaglutideConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C152328SemaglutideOne source FDA
  • DrugBank DB13928One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion